FDA Approved 3 New Indications in Oncology in June-July 2022

FDA Approved 3 New Indications in Oncology in June-July 2022

The US FDA approved three new indications for cancer management between 1 June and 31 July, 2022. Dabrafenib Plus Trametinib for BRAF...

Intensive Follow-up Does Not Improve Survival in Endometrial Cancer

Intensive Follow-up Does Not Improve Survival in Endometrial Cancer

Endometrial cancer is among the most common gynecological cancers in Europe. Fortunately, most patients present with operable disease which has a good...

Adjuvant Toripalimab vs. High-Dose Interferon in Mucosal Melanoma: Similar Efficacy, Better Tolerability

Adjuvant Toripalimab vs. High-Dose Interferon in Mucosal Melanoma: Similar Efficacy, Better Tolerability

Mucosal melanoma (MM) is rare in the West, but in Asia it is the second most common melanoma subtype, accounting for about...

Acetaminophen May Hinder Immunotherapy Efficacy in Cancer

Acetaminophen May Hinder Immunotherapy Efficacy in Cancer

Immune checkpoint inhibitors (ICIs) have changed the paradigm of cancer treatment, and indications for their use are expanding. In addition to specific...

First-Line Brentuximab Vedotin Combo Best in Advanced Hodgkin Lymphoma

First-Line Brentuximab Vedotin Combo Best in Advanced Hodgkin Lymphoma

Classic Hodgkin lymphoma (cHL) is highly curable with frontline therapy. However, around 20% of patients with advanced stage III/IV disease tend to...

Nephrotoxicity Associated With Immune Checkpoint Inhibitors

Nephrotoxicity Associated With Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) that target cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death receptor 1 (PD-1) are having a marked...